MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat discussing the company’s pipeline of novel obesity and metabolic therapies. This event will take place at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Wednesday, June 24, 2026, at 10:30 am ET.

The forum will be a live, interactive online event where investors can ask questions in real-time. For those unable to attend the live session, an archived webcast will be available after the event concludes.

Investors are encouraged to pre-register and conduct an online system check to facilitate participation and receive event updates.

MetaVia will also be available for one-on-one meetings, and interested investors may register for these discussions. For additional scheduling outside the conference, inquiries can be directed to Michael Miller at [email protected].

MetaVia is currently developing DA-1726 for the treatment of obesity and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 functions as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). Its potential for weight loss has been highlighted in a Phase 1 trial, where it demonstrated promising results for weight loss, glucose control, and waist reduction. Vanoglipel is being studied as a first-in-class candidate targeting G-protein-coupled receptor 119 (GPR119) and has shown positive metabolic effects and differentiated hepatic benefits in preclinical studies and a Phase 2a clinical study.

For further details, more information is available at www.metaviatx.com.